Shares of Novavax fell by a staggering 10.61% to $174.42 at 14:38 EST on Tuesday, after four sequential sessions in a row of losses. NASDAQ Composite is sliding 2.48% to $13,550.11, after two successive sessions in a row of losses. This seems, up until now, an all-around rough trend exchanging session today.

Novavax’s last close was $195.12, 90.16% below its 52-week high of $331.68.

Novavax’s Sales

Novavax’s sales growth is 6826.3% for the present quarter and 1558.1% for the next. The company’s growth estimates for the ongoing quarter is a negative 520.7% and positive 250% for the next.

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 3072.2%, now sitting on 475.6M for the twelve trailing months.

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $174.42 at 14:38 EST, way under its 52-week high of $331.68 and way higher than its 52-week low of $14.38.

Novavax’s Moving Average

Novavax’s worth is way under its 50-day moving average of $210.81 and way higher than its 200-day moving average of $149.03.

Previous days news about Novavax

Novavax begins testing its Covid-19 vaccine candidate in teens. According to MarketWatch on Monday, 3 May, "Shares of Novavax Inc. gained 0.6% in trading on Monday after the biotechnology firm said it has expanded its Phase 3 clinical trial for its COVID-19 vaccine candidate to include 12 to 17 year olds in the U.S. Novavax’s experimental vaccine is currently being tested in a late-stage trial that began in December in the U.S. and Mexico. "

More news about Novavax.


Please enter your comment!
Please enter your name here